ITM Isotope Technologies Munich SE (Debt Financing)
Funding Details
- Awarder
- RSS - techfundingnews.com
- Date Award
- May 28, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $262,500,000
Company Info
- Founding Year
- 2004
- Traction
- ITM has met primary endpoints in its Phase 3 COMPETE trial for gastroenteropancreatic neuroendocrine tumors and plans to submit a New Drug Application to the U.S. FDA in 2025.
- Founders
- Dr. Andrew Cavey
- Company Description
- ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech firm focused on developing precision oncology treatments, particularly for hard-to-treat neuroendocrine tumors. The company is advancing its lead candidate, ITM-11, through late-stage clinical trials and aims to establish a global supply of non-carrier-added Lutetium-177.
- Market
- Radiopharmaceuticals
- Location
- Munich, Germany
- Coinvestors
- Blue Owl Capital